EP4408439A4 - Rhenium nanomaterial-based inhibitors of inflammation and cancer metastases - Google Patents

Rhenium nanomaterial-based inhibitors of inflammation and cancer metastases

Info

Publication number
EP4408439A4
EP4408439A4 EP22877643.1A EP22877643A EP4408439A4 EP 4408439 A4 EP4408439 A4 EP 4408439A4 EP 22877643 A EP22877643 A EP 22877643A EP 4408439 A4 EP4408439 A4 EP 4408439A4
Authority
EP
European Patent Office
Prior art keywords
nanomaterial
rhenium
inflammation
based inhibitors
cancer metastases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22877643.1A
Other languages
German (de)
French (fr)
Other versions
EP4408439A1 (en
Inventor
Kam W Leong
Yiling Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewSouth Innovations Pty Ltd
Columbia University in the City of New York
Original Assignee
NewSouth Innovations Pty Ltd
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NewSouth Innovations Pty Ltd, Columbia University in the City of New York filed Critical NewSouth Innovations Pty Ltd
Publication of EP4408439A1 publication Critical patent/EP4408439A1/en
Publication of EP4408439A4 publication Critical patent/EP4408439A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ceramic Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP22877643.1A 2021-09-30 2022-09-30 Rhenium nanomaterial-based inhibitors of inflammation and cancer metastases Pending EP4408439A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163250311P 2021-09-30 2021-09-30
US202263305340P 2022-02-01 2022-02-01
PCT/US2022/077427 WO2023056470A1 (en) 2021-09-30 2022-09-30 MnO NANOMATERIAL BASED INHIBITORS OF INFLAMMATION AND CANCER METASTASIS

Publications (2)

Publication Number Publication Date
EP4408439A1 EP4408439A1 (en) 2024-08-07
EP4408439A4 true EP4408439A4 (en) 2025-07-30

Family

ID=85783698

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22877643.1A Pending EP4408439A4 (en) 2021-09-30 2022-09-30 Rhenium nanomaterial-based inhibitors of inflammation and cancer metastases

Country Status (4)

Country Link
EP (1) EP4408439A4 (en)
JP (1) JP2024537825A (en)
CA (1) CA3233706A1 (en)
WO (1) WO2023056470A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116135236B (en) * 2023-03-09 2024-07-19 东华大学 A photothermal fiber composite hydrogel dressing and preparation method thereof
CN119971070A (en) * 2025-02-12 2025-05-13 山东第一医科大学附属眼科医院(山东省眼科医院) A photothermal-photodynamic integrated antibacterial nanomedicine and its preparation method and application in the preparation of biofilm-related keratitis drugs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100251856A1 (en) * 2009-04-03 2010-10-07 Venugopal Santhanam Methods for preparing metal and metal oxide nanoparticles
CN108030933A (en) * 2017-12-13 2018-05-15 北京工商大学 A kind of high sensitivity bimodal magnetic resonance contrast agent and preparation method thereof
CN109833476A (en) * 2017-11-28 2019-06-04 深圳先进技术研究院 A kind of targeting specific response tumor microenvironment nanometric photosensitizer and its preparation method and application
US20190192656A1 (en) * 2014-04-03 2019-06-27 The Governing Council Of The University Of Toronto Multifunctional nanoparticle compositions and uses thereof
US20200390807A1 (en) * 2018-02-20 2020-12-17 University Of Florida Research Foundation, Incorporated Composition and method for targeting natural killer cells in immunotherapy to overcome tumor suppression with manganese dioxide nanoparticles
CN114796598A (en) * 2022-05-06 2022-07-29 南京工业大学 Antibacterial hydrogel for promoting healing of refractory wound surface and application thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100251856A1 (en) * 2009-04-03 2010-10-07 Venugopal Santhanam Methods for preparing metal and metal oxide nanoparticles
US20190192656A1 (en) * 2014-04-03 2019-06-27 The Governing Council Of The University Of Toronto Multifunctional nanoparticle compositions and uses thereof
CN109833476A (en) * 2017-11-28 2019-06-04 深圳先进技术研究院 A kind of targeting specific response tumor microenvironment nanometric photosensitizer and its preparation method and application
CN108030933A (en) * 2017-12-13 2018-05-15 北京工商大学 A kind of high sensitivity bimodal magnetic resonance contrast agent and preparation method thereof
US20200390807A1 (en) * 2018-02-20 2020-12-17 University Of Florida Research Foundation, Incorporated Composition and method for targeting natural killer cells in immunotherapy to overcome tumor suppression with manganese dioxide nanoparticles
CN114796598A (en) * 2022-05-06 2022-07-29 南京工业大学 Antibacterial hydrogel for promoting healing of refractory wound surface and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN LI ET AL: "Nanotherapies for sepsis by regulating inflammatory signals and reactive oxygen and nitrogen species: New insight for treating COVID-19", REDOX BIOLOGY, vol. 45, 1 September 2021 (2021-09-01), NL, pages 1 - 15, XP093060720, ISSN: 2213-2317, DOI: 10.1016/j.redox.2021.102046 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1 December 2019 (2019-12-01), ADHIKARI A ET AL: "Nano sized Mn3O4 can treat hepatic fibrosis: Alteration in route of administration gives a new twist to the tale", XP002813546, Database accession no. EMB-631896253 *
See also references of WO2023056470A1 *

Also Published As

Publication number Publication date
WO2023056470A1 (en) 2023-04-06
JP2024537825A (en) 2024-10-16
EP4408439A1 (en) 2024-08-07
CA3233706A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
EP4472967A4 (en) IRAQ-DECORDERS AND USES OF THEM
IL286352A (en) New small molecule inhibitors of tead transcription factors
EP4524136A4 (en) Kinesin-KIF18A inhibitors and uses thereof
DK4181920T3 (en) CAT6 INHIBITOR AND COMBINATIONS FOR THE TREATMENT OF BREAST CANCER
IL283592A (en) Apol1 inhibitors and methods of using them
EP4408439A4 (en) Rhenium nanomaterial-based inhibitors of inflammation and cancer metastases
EP4463166A4 (en) IRAQ-4 DEMOCRAFT AND USES OF IT
EP4081202A4 (en) ENHANCED TRANSCRIPTIONAL DOMAIN ASSOCIATED (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF
EP4196941A4 (en) VERSATILE POINT OF SALES SYSTEMS AND PROCEDURES
EP4499068A4 (en) IRAQ-DECORDERS AND USES OF THEM
EP3930709A4 (en) LIPID PRODRUGS OF JAK INHIBITORS AND THEIR USES
EP4509505A4 (en) KIF18A inhibitors and their use
IL299840A (en) Inhibitors of complement factors and their uses
EP3592731A4 (en) INHIBITORS OF MALT1 AND USES THEREOF
HRP20251592T1 (en) ARGINASE INHIBITORS AND METHODS OF THEIR APPLICATION
EP4450501A4 (en) CDK9 HIBITOR AND USE OF IT
IL299700A (en) KCNT1 inhibitors and methods of use
EP4225310A4 (en) HETEROARYLAMIDE INHIBITORS OF CD38
EP4452934A4 (en) IONIZABLE DISULFIDLIPIDS AND LIPIDNANOPARTICLES DERIVED THEM
EP4192836A4 (en) ATR INHIBITORS AND USES THEREOF
EP4458823A4 (en) Meniamine inhibitors and their use
EP4244205A4 (en) IRE1ALPHA INHIBITORS AND USES THEREOF
EP3965750A4 (en) CANCER STRATIFICATION AND TREATMENT BASED ON INHIBITION OF NOD-2
EP4161917A4 (en) GRK2 INHIBITORS AND USES THEREOF
EP4536239A4 (en) GPCR inhibitors and their uses

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250701

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/74 20060101AFI20250625BHEP

Ipc: A61K 47/56 20170101ALI20250625BHEP

Ipc: A61K 47/59 20170101ALI20250625BHEP

Ipc: A61K 47/69 20170101ALI20250625BHEP

Ipc: A61P 29/00 20060101ALI20250625BHEP

Ipc: A61P 35/00 20060101ALI20250625BHEP

Ipc: A61P 35/04 20060101ALI20250625BHEP